Cannabigerol (CBG) is poised to make a substantial impact in the pharmaceutical and consumer goods markets, and researchers worldwide are investigating CBG’s potential medical benefits. To meet the growing need for CBG, High Grade Hemp Seed and Swiss Cannabinoid are pleased to introduce Matterhorn, a new high-CBG varietal that could open up production and make cannabigerol a viable force in the hemp industry. Previous varietals of CBG contained low quantities of the cannabinoid, making growing hemp for focused CBG production cost-prohibitive…
Hemp Industry Daily Conference Direct
Hemp Industry Daily Conference Direct is exclusively designed to bring the leaders in the hemp industry together in a state-of-the-art online environment to learn, discuss, network and chart the future of our industry as we look to emerge stronger than ever from these uncertain times.LEARN MORE
U.S. hemp sales could increase as much as $25 million in 2020 and by more than $100 million in 2022, according to new estimates by the U.S. Department of Agriculture (USDA).Read More
Optimism around a three-day hemp auction in Tennessee turned to disappointment when producers found way more sellers than buyers, driving prices down and leaving some frustrated. But organizers of the inaugural International Hemp Auction and Market, modeled after tobacco auctions in the area, say the market volatility will settle down, making future auctions more valuable. The […]Read More
The CBD marketplace grows more crowded by the day, with manufacturers struggling to gain market share in a sea of CBD products all claiming to be the most effective. That makes branding and marketing essential for even a savvy cannabis entrepreneur hoping to gain traction in a confusing and congested market, where every product starts […]Read More
After a seasonlong struggle associated with banking and financing their operations, hemp farmers and businesses can exhale now that federal and state financial institutions have loosened reporting restrictions on hemp banking and issued guidance to members.Read More
Hemp might be legal now, but more and more hemp companies are finding themselves in court. That’s because the booming industry has attracted a mix of new entrepreneurs and get-rich-quick scam artists looking to take advantage of a new market with few established players. Making matters more complicated for hemp businesses is the fact that many […]Read More
Why would a CBD company want to try and enter the mainstream retail market through the labyrinth that is convenience stores and gas stations?Read More
What better bedfellows to collaborate on a new sleep-aid product than a CBD company and a mattress maker?
That thought was the genesis of a collaboration between Plus Products of San Mateo, California, and New York-based mattress firm Casper Sleep.Read More
When President Donald Trump signed the 2018 Farm Bill into law, it not only made hemp a legal crop on the federal level, it also made cannabis-derived products more obtainable to consumers beyond marijuana retailers.
A side effect of this development is that securing a partnership with mainstream retail companies has become the goal of every cannabis business hoping to reach more customers and potentially see a huge increase in sales.Read More
Federal health officials are standing firm against cannabidiol use in food, issuing a fresh round of warnings to companies making CBD edibles. The U.S. Food and Drug Administration (FDA) said Monday that it “cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for its use in human or animal food” based […]Read More
CBD manufacturers have seen wide adoption of their products into mainstream retail chains in recent months, so why aren’t they turning profits as rapidly as expected? The federal government is the culprit, according to some. CV Sciences and Charlotte’s Web are among the cannabis companies that pointed to delayed federal CBD regulations as they reported […]Read More
Federal health regulators say the lack of scientific data about cannabidiol explains their delay issuing new guidance on over-the-counter CBD products. The U.S. Food and Drug Administration (FDA) continues to accept comments on hemp- and cannabis-derived ingredients, months after the comment period closed, according to Sharon Lindan Mayl, senior policy adviser in the agency’s Office […]Read More